Toronto Dominion Bank Reduces Stock Holdings in Charles River Laboratories International, Inc. (NYSE:CRL)

Toronto Dominion Bank decreased its position in shares of Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 32.3% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 17,336 shares of the medical research company's stock after selling 8,281 shares during the quarter. Toronto Dominion Bank's holdings in Charles River Laboratories International were worth $3,200,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Veracity Capital LLC acquired a new position in shares of Charles River Laboratories International during the 4th quarter valued at about $589,000. Allspring Global Investments Holdings LLC raised its holdings in Charles River Laboratories International by 2.7% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 1,808,002 shares of the medical research company's stock valued at $330,231,000 after buying an additional 47,221 shares during the period. Mirae Asset Global Investments Co. Ltd. raised its holdings in Charles River Laboratories International by 46.4% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,301 shares of the medical research company's stock valued at $987,000 after buying an additional 1,679 shares during the period. Boston Trust Walden Corp raised its holdings in Charles River Laboratories International by 4.3% in the 4th quarter. Boston Trust Walden Corp now owns 204,483 shares of the medical research company's stock valued at $37,748,000 after buying an additional 8,338 shares during the period. Finally, E. Ohman J or Asset Management AB raised its holdings in Charles River Laboratories International by 225.0% in the 4th quarter. E. Ohman J or Asset Management AB now owns 2,600 shares of the medical research company's stock valued at $480,000 after buying an additional 1,800 shares during the period. Institutional investors and hedge funds own 98.91% of the company's stock.

Charles River Laboratories International Stock Up 1.8%

Shares of CRL stock traded up $2.52 during trading hours on Tuesday, reaching $139.25. 379,912 shares of the stock were exchanged, compared to its average volume of 991,620. The business's fifty day moving average is $131.30 and its two-hundred day moving average is $162.22. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.41 and a quick ratio of 1.14. Charles River Laboratories International, Inc. has a 12-month low of $91.86 and a 12-month high of $254.15. The firm has a market capitalization of $6.84 billion, a P/E ratio of 928.07, a P/E/G ratio of 4.54 and a beta of 1.50.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last released its earnings results on Wednesday, May 7th. The medical research company reported $2.34 earnings per share for the quarter, topping analysts' consensus estimates of $2.06 by $0.28. Charles River Laboratories International had a net margin of 0.52% and a return on equity of 14.69%. The firm had revenue of $984.17 million for the quarter, compared to analyst estimates of $942.34 million. During the same period in the prior year, the firm earned $2.27 earnings per share. The business's quarterly revenue was down 2.7% compared to the same quarter last year. As a group, research analysts expect that Charles River Laboratories International, Inc. will post 9.36 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on CRL. Evercore ISI upgraded shares of Charles River Laboratories International from an "in-line" rating to an "outperform" rating and set a $170.00 price objective on the stock in a report on Thursday, May 8th. The Goldman Sachs Group lowered shares of Charles River Laboratories International from a "buy" rating to a "neutral" rating and reduced their price objective for the company from $190.00 to $170.00 in a report on Friday, March 21st. Citigroup upgraded shares of Charles River Laboratories International from a "sell" rating to a "neutral" rating and boosted their price objective for the company from $155.00 to $175.00 in a report on Tuesday, March 4th. Robert W. Baird boosted their price objective on shares of Charles River Laboratories International from $118.00 to $140.00 and gave the company a "neutral" rating in a report on Thursday, May 8th. Finally, Mizuho reduced their price objective on shares of Charles River Laboratories International from $175.00 to $155.00 and set a "neutral" rating on the stock in a report on Wednesday, April 9th. One investment analyst has rated the stock with a sell rating, thirteen have given a hold rating and four have issued a buy rating to the company's stock. According to data from MarketBeat.com, Charles River Laboratories International presently has an average rating of "Hold" and an average price target of $171.85.

Insider Activity at Charles River Laboratories International

In related news, EVP Joseph W. Laplume sold 500 shares of the company's stock in a transaction that occurred on Tuesday, May 13th. The stock was sold at an average price of $145.41, for a total value of $72,705.00. Following the completion of the transaction, the executive vice president now directly owns 19,513 shares of the company's stock, valued at $2,837,385.33. This represents a 2.50% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 1.30% of the stock is currently owned by corporate insiders.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).